Podcast Episodes
Back to Search
Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo; Gilead's $3.15B Tubulis ADC Acquisition
Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront …
3 months, 2 weeks ago
Apr 07, 2026 | Pharma Tariffs Hit 100% with Major Loopholes; Gilead's $3.15B Tubulis ADC Deal
100% tariffs on branded drug imports took effect — but thecarve-outs may matter more than the rate. Gilead acquires ADC maker Tubulis for $3.15B upfr…
3 months, 2 weeks ago
Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet
Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B…
3 months, 2 weeks ago
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back…
3 months, 2 weeks ago
Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree
Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight day…
3 months, 2 weeks ago
Apr 02, 2026 | Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved
Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval …
3 months, 3 weeks ago
Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials
Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoint…
3 months, 3 weeks ago
Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026
Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spre…
3 months, 3 weeks ago
Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data
United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 3…
3 months, 3 weeks ago
Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026
Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 …
3 months, 3 weeks ago